Algae Oil

Evidence Fact Sheet

Educational reference on algae oil — a plant-derived, closed-system fermentation source of long-chain omega-3 fatty acids. Sibling reference to our Omega-3 cluster hub and Fish Oil sub-page. Evidence-graded, regulator-aligned, supplier-brand-neutral.

Last reviewed 2026-05-24 · How we assess evidence →

Quick Summary

Algae oil is a long-chain omega-3 source produced by closed-system fermentation of single-celled microalgae — the same organisms at the base of the marine food chain that fish indirectly accumulate DHA and EPA from. Most commercial algae oil is DHA-dominant with very low EPA (typically 35–55% DHA, <3% EPA), because the dominant production strains (Schizochytrium sp., Crypthecodinium cohnii, Ulkenia amoeboida) preferentially synthesize DHA. A separate microalga, Nannochloropsis sp., is EPA-rich but commercially uncommon.

In head-to-head bioequivalence testing, algae DHA delivered as a capsule produced the same plasma and red-blood-cell DHA incorporation as DHA from cooked salmon (Arterburn 2008, n=32 RCT, PMID 18589030). The clinical differentiation between algae and fish oils is therefore not in DHA delivery efficiency — it is in purity, source-chain ethics, and applicability to populations who cannot or will not consume fish: vegans, kosher and halal observers, vegetarian Hindu and Buddhist populations, pregnant women concerned about marine contaminants, and the global infant-formula supply chain (in which algae oil is the standard DHA source).

Algae oil also has well-defined limitations that this page does not hide. It typically costs 2–4× fish oil per mg of EPA+DHA. Its DHA-dominant profile is not the best match for clinical scenarios in which EPA drives the effect (major depressive disorder adjunct, prescription-strength cardiovascular event prevention). And in Brazil, food-supplement use of algae oil is restricted to adults ≥19 years (ANVISA IN 28/2018), a constraint enforced by a 2023 VISA/SC suspension of multiple children-targeted algae DHA products.

What Is Algae Oil

Algae oil is a plant-derived, closed-system fermentation source of long-chain omega-3 fatty acids that in head-to-head bioequivalence testing delivered the same plasma and red-blood-cell DHA incorporation as DHA from cooked salmon (Arterburn 2008, n=32 RCT, PMID 18589030).

Algae oil is the lipid fraction extracted from cultivated microalgae and refined into a food-grade oil. The microalgae are grown in closed-system fermentation tanks — industrial bioreactors (5–200 m³) running on food-grade carbohydrate, mineral salts, and trace nutrients at controlled temperature, pH, and aeration — and harvested for their long-chain omega-3 lipids.

This matters because marine fish do not synthesize EPA or DHA themselves. The omega-3 in fish oil is biosynthesized by microalgae at the base of the marine food chain, then accumulated up the chain into fish tissue (and, in parallel, into the contaminants that biomagnify alongside it). Algae oil is therefore not an "alternative" to fish oil — it is the biosynthetic origin of marine omega-3, taken directly from the source rather than recovered from higher in the food web.

The four microalgae that account for nearly all commercial algae oil have meaningfully different fatty-acid profiles, regulatory pedigrees, and use cases:

Microalga	Typical lipid profile	Primary use	Regulatory anchor
Schizochytrium sp. (Thraustochytrid)	DHA 35–55% · EPA <3%	Global infant-formula DHA · adult DHA supplements · food fortification	FDA GRAS Notice 137 (2004) · EFSA Novel Food (EFSA Journal 2020;18(10):6242) · Reg (EU) 2017/2470 Union List · China MOH 2010 Notice No. 3
Crypthecodinium cohnii (dinoflagellate)	DHA 40–50% · EPA ~0	"Pure DHA" infant-formula applications where EPA is not desired	EU Decision 2003/427/EC (original Novel Food authorization · 2003) · FDA GRAS · China MOH 2010 Notice No. 3
Ulkenia amoeboida (Thraustochytrid)	DHA 30–45% · EPA <3%	Infant formula and adult DHA · similar profile to Schizochytrium	China MOH 2010 Notice No. 3 (explicitly listed alongside Schizochytrium and C. cohnii)
Nannochloropsis sp. (Eustigmatophyceae)	EPA 25–35% · DHA <5%	The only scalable plant-derived EPA route · rare in supplements · common in aquaculture feed	EFSA Novel Food (multiple strain-specific authorizations granted and in progress) · partial FDA GRAS

When this page refers to "algae oil" without qualification, it means the DHA-dominant Schizochytrium / Crypthecodinium / Ulkenia segment — which constitutes the great majority of commercial algae oil products. Nannochloropsis-derived EPA is discussed separately in the Algae EPA section below.

EPA:DHA Ratio — Why Algae Oil Is DHA-Dominant

Algae oil from Schizochytrium sp. / Crypthecodinium cohnii / Ulkenia amoeboida synthesizes DHA through a PUFA-polyketide-synthase (PUFA-PKS) pathway with terminal product heavily biased toward DHA (C22:6 n-3), while DHA integrates into cell membrane phospholipids (~40% of brain phospholipid PUFA · ~50% of retinal rod outer-segment PUFA) and supports pro-resolving mediator synthesis, PPAR-α activation, and GPR120/FFAR4 receptor activation.

The fatty-acid profile of algae oil differs fundamentally from fish oil, and within algae oil the profile differs sharply between strains. The table below shows where each source sits.

Source	Typical EPA %	Typical DHA %	EPA:DHA ratio
Fish oil (natural blend)	18–30%	12–22%	~1.5 : 1
Fish oil (high-concentration rTG / EE)	30–55%	20–45%	tunable 1:1 to 7:3
*Algae oil (Schizochytrium* / C. cohnii)**	<3%	35–55%	~1 : 15 to 1 : 30 (DHA dominant)
Algae oil (Nannochloropsis)	25–35%	<5%	~5 : 1 to 8 : 1 (EPA dominant)

The biological reason for the Schizochytrium / C. cohnii DHA-dominance is enzymatic: Thraustochytrid microalgae synthesize DHA through a PUFA-polyketide-synthase (PUFA-PKS) pathway rather than the classical Δ-desaturase pathway found in most other organisms. Their terminal product is heavily biased toward DHA (C22:6 n-3), with EPA (C20:5 n-3) appearing only at trace levels. Crypthecodinium cohnii reaches the same end via a non-classical pathway, with even less EPA. Nannochloropsis uses a different pathway that terminates earlier, yielding mostly EPA.

This ratio matters clinically because DHA and EPA are not interchangeable. DHA is a structural component of brain phospholipids (~40% of brain phospholipid PUFA) and the retinal rod outer segment (~50% of retinal PUFA), and is the form whose maternal intake is recognized by EFSA as contributing to normal fetal brain and eye development. EPA, in contrast, is the form with the strongest evidence in major depressive disorder adjunctive therapy (EPA-dominant formulations) and in prescription-strength cardiovascular event prevention (the 4 g/d pure-EPA REDUCE-IT trial).

The practical implication: algae oil from Schizochytrium or C. cohnii is well-matched to brain, vision, pregnancy, infant, and cognitive-aging applications, and is not well-matched to MDD adjunctive use or high-dose cardiovascular event prevention — where EPA carries the evidence. For those uses, fish oil (especially EPA-dominant or pure-EPA prescription formulations) is the better-supported choice. (See our Omega-3 cluster hub for the full EPA-vs-DHA mechanism breakdown.)

Who Algae Oil Is For — Four Independent Differentiators

Algae oil's evidence base does not establish that it produces "better" outcomes than fish oil in shared applications. Its case rests on four independent differentiators, each of which stands on its own.

Plant-derived diets and religious dietary observance

Algae oil is plant-derived and contains no animal tissue, fish protein, or shellfish allergen. This makes it the appropriate long-chain omega-3 source for several large global populations that fish oil cannot serve, or can serve only with friction:

Vegans and strict vegetarians — fish oil is excluded by definition; algae oil is the only scalable direct source of EPA / DHA.
Lacto-ovo vegetarians, Hindu vegetarians (~ a billion+ people across India and the diaspora), and Buddhist vegetarian traditions — algae oil is preferred.
Kosher — fish meeting kosher rules can yield kosher fish oil, but algae oil is more straightforwardly certifiable because closed-system fermentation removes ambiguity about the source organism.
Halal — same logic; algae oil from a certified-halal facility avoids questions about the fish-source supply chain.

A critical companion point — covered in detail on our Omega-3 cluster hub — is that plant-derived alpha-linolenic acid (ALA, from flaxseed or chia) does not efficiently convert to EPA or DHA in humans. Whole-body conversion of ALA to DHA is typically below 5% in adults and lower in men. For people who avoid fish on dietary or religious grounds, algae oil is the most reliable way to achieve the long-chain omega-3 intakes referenced by NIH-ODS, WHO, and EFSA.

Pregnancy

International nutrition bodies converge on ≥200 mg DHA per day during pregnancy (WHO, ISSFAL, EFSA, ACOG, China dietary guidelines). EFSA has authorized an Article 14 health claim that "maternal intake of docosahexaenoic acid contributes to the normal brain and eye development of the fetus and breastfed infants," supported by an additional intake of 200 mg DHA per day on top of the adult background recommendation.

Algae oil's two relevant attributes in pregnancy are:

Zero exposure to marine contaminants by source chain — no mercury, PCBs, dioxins, or microplastics from oceanic origin to cross the placental barrier. Fish-source contaminant placental transfer is well-documented in epidemiologic literature; algae oil produced by closed-system fermentation does not introduce these contaminants in the first place.
Direct RCT evidence at supraphysiological dose — the DOMInO trial (Makrides 2010, JAMA, PMID 20959577, n=2,399 Australian pregnant women) tested 800 mg DHA + 100 mg EPA per day from mid-pregnancy onward, sourced from algae and fish oil. See the Algae-Specific Evidence section below for the full evidence summary, including important caveats.

Infant nutrition

Infants synthesize DHA poorly and depend on dietary DHA — from breast milk (whose DHA content tracks maternal intake) or from DHA-fortified infant formula — to meet rapid neurodevelopmental needs. Global infant-formula regulations have converged on requiring or strongly encouraging DHA fortification:

China GB 10765-2021 mandates DHA at 0.2–0.5% of total fatty acids in infant formula.
FAO / WHO 2010 guideline endorses DHA fortification.
US FDA 21 CFR 107 permits DHA addition.
EU Directive 2006/141/EC (now Regulation 2016/127) requires DHA addition.

Essentially all globally marketed infant-formula DHA comes from algae oil. Fish oil is not used in infant formula because of fishy odor, fish-allergen cross-reactivity concerns, and contaminant-control difficulty. This is a structural, regulator-driven adoption of algae oil — not a marketing claim.

A critical regulatory distinction: the infant-formula DHA channel and the food-supplement channel are governed by different rules. In Brazil, ANVISA IN 28/2018 restricts algae oil food supplements to consumers aged ≥19 years; algae oil in infant formula is permitted under separate regulation. The 2023 VISA/SC suspension of "True Source Liquid DHA for Baby & Kids" and similar pediatric-positioned algae DHA supplements is a direct enforcement of this distinction. Brazilian consumers should buy DHA for children only via approved infant-formula or pediatric channels.

Marine-contaminant sensitivity and sustainability priorities

Algae oil's closed-system fermentation produces no exposure to mercury, polychlorinated biphenyls, dioxins, dioxin-like compounds, or oceanic microplastics. Independent contaminant testing of refined algae oil typically reports all four heavy metals (Hg, Pb, Cd, As) and PCB sums at below detection limit (BDL) — i.e., below the lower bound of standard laboratory quantification, not merely below the regulatory permissible maximum. Fish oil purity varies widely; reputable third-party programs (IFOS 5-star, GOED voluntary monograph compliance) reduce contaminant levels substantially but cannot completely eliminate them, because the source chain itself accumulates them.

Algae oil also avoids the wild-fishery dependency of the global fish oil supply chain: approximately three-quarters of world fish oil production is consumed by aquaculture, which itself drives further wild-fish extraction. Closed-system algae fermentation breaks this loop entirely.

For consumers prioritizing marine-contaminant avoidance (including pregnant women and people with autoimmune conditions sensitive to environmental toxicants) or marine-ecosystem impact, algae oil is the structurally lower-impact choice — at typically 2–4× the cost per mg EPA+DHA.

Algae-Specific Evidence

This section is restricted to evidence drawn from RCTs and meta-analyses that specifically used algae-derived DHA (or, in the Algae EPA subsection, algae EPA). Broad EPA / DHA evidence is reviewed in the Omega-3 cluster hub.

Bioequivalence with cooked salmon — Arterburn 2008 (PMID 18589030)

RCT supported

Algae DHA delivered as a capsule produced the same plasma and red-blood-cell DHA incorporation as DHA from cooked salmon in head-to-head testing.

n=32RCT participants
600 mg DHA/dstudy dose
bioequivalentincorporation outcome

Design: Open-label parallel-group RCT in 32 healthy adults aged 20–65, randomized to 600 mg DHA per day for two weeks, delivered either as algae oil capsules or as cooked salmon.

Findings: Plasma phospholipid DHA and erythrocyte DHA rose to statistically equivalent levels in both arms. Algae DHA achieved the same incorporation into circulating and red-cell phospholipids as DHA from a whole-food fish source.

Why it matters: This is the cornerstone evidence that algae DHA and fish-derived DHA are biologically equivalent at the level of delivery to body tissues. The differentiation between algae oil and fish oil rests on dietary suitability, purity, and source-chain sustainability — not on superior or inferior bioavailability.

Triglycerides and lipid profile — honest two-direction findings

Meta-analysis supported

Algae DHA significantly reduces serum triglycerides but also modestly raises both HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease.

11 RCTsmeta-analysis scope
TG ↓ + HDL-C ↑ + LDL-C ↑lipid endpoints
16 RCTsclinical overview

Citation	PMID	Type	Headline finding
Bernstein AM et al. 2012, J Nutr 142(1):99–104	22113870	Meta-analysis of 11 RCTs	Algae oil DHA significantly reduced serum triglycerides and significantly raised both HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease.
Ryan AS et al. 2009, Cardiovasc Drugs Ther	19145206	Clinical overview of 16 RCTs	Algae DHA reduces serum triglycerides across normotriglyceridemic, hypertriglyceridemic, and statin-treated populations. (Note: author affiliations include the algae oil ingredient supplier — disclosure consistent with educational-reference practice.)
Maki KC et al. 2014, Prostaglandins Leukot Essent Fatty Acids	25123060	RCT	A microalgae oil providing both DHA and EPA (i.e., not pure Schizochytrium DHA — a dual-strain or EPA-enriched microalgae formulation) lowered triacylglycerols in adults with mild-to-moderate hypertriglyceridemia.

Honest interpretation: Algae DHA does lower serum triglycerides, supported by an 11-RCT meta-analysis. That same meta-analysis also reports that algae DHA raises LDL-cholesterol modestly alongside the rise in HDL-cholesterol — a real, two-direction lipid effect that any complete description of algae DHA's cardiovascular profile must include.

For cardiovascular event prevention (MACE — myocardial infarction, stroke, cardiovascular death), the strongest evidence in the omega-3 field is REDUCE-IT (Bhatt 2019, PMID 30415628), which used 4 g per day of pure prescription EPA (icosapent ethyl) in statin-treated high-risk patients with elevated triglycerides. There is no comparable large-outcome trial of algae DHA for cardiovascular event prevention. Algae DHA's evidence base is in triglyceride modification, brain, vision, pregnancy, and infant development — not as a substitute for prescription-strength EPA in secondary cardiovascular prevention.

Pregnancy — DOMInO trial (Makrides 2010, PMID 20959577)

RCT supported (negative primary endpoints)

High-dose DHA in pregnancy (800 mg DHA + 100 mg EPA/d) showed negative primary outcomes on maternal depression and infant cognition but reported as a secondary finding approximately 50% relative reduction in early preterm births with post-term gestation signal.

n=2,399Australian pregnant women
800 mg DHA + 100 mg EPA/dintervention dose
~50% ↓early preterm <34 wk

The DOMInO (DHA to Optimise Mother Infant Outcome) trial is the largest and most-cited single RCT of high-dose DHA in pregnancy.

Design: Double-blind, placebo-controlled RCT, n=2,399 Australian pregnant women. Intervention group received 800 mg DHA + 100 mg EPA per day (sourced from algae and fish oils) from approximately 21 weeks gestation through delivery; control group received vegetable-oil placebo capsules.

Pre-specified primary endpoints (what the trial was designed to test):

Maternal postpartum depression at 6 months — no significant difference between DHA and placebo groups.
Cognitive and language development in children at 18 months (Bayley Scales) — no significant difference between groups.

The trial's primary endpoints, in other words, were negative: high-dose DHA in pregnancy did not reduce postpartum depression or improve early-childhood cognitive scores in this large, well-conducted study.

Secondary outcomes — analyzed alongside but distinct from the primary endpoints — included pregnancy-duration measures. The DHA group showed:

Early preterm birth (delivery before 34 weeks): 1.1% vs 2.2% in controls (a relative reduction of approximately 50%, absolute difference 1.1 percentage points, number-needed-to-treat approximately 90). Because this is a secondary outcome from a trial whose primary endpoints were negative, it should be interpreted as hypothesis-generating, not as a definitive demonstration that DHA prevents early preterm birth.
Post-term induction of labor and post-term pre-labor caesarean delivery: increased in the DHA group — a safety signal indicating that high-dose DHA may modestly prolong gestation in some women, with a small fraction requiring obstetric intervention.

A note on dose precision: the DOMInO regimen was 800 mg DHA plus 100 mg EPA per day, not 800 mg of pure DHA. Descriptions of DOMInO as a "pure DHA" trial are imprecise.

The supporting evidence beyond DOMInO is the Cochrane systematic review by Middleton et al. 2018 (PMID 30480773), which pooled 70 RCTs (n=19,927) including DOMInO and reported a relative reduction in early preterm birth (<34 weeks) of approximately 42% with omega-3 supplementation in pregnancy. This Cochrane synthesis is the most defensible pooled estimate.

What this means in practice: WHO, ISSFAL, EFSA, and obstetric guidelines support ≥200 mg DHA per day during pregnancy for fetal brain and eye development. Algae oil is a regulator-aligned source. Higher-dose use (toward the DOMInO 800-mg level) should be a clinical conversation with an obstetric care provider, given the post-term gestation signal and the negative findings on primary maternal-depression and infant-cognition endpoints.

Algae EPA — sparse evidence, single bioavailability RCT

Evidence specific to Nannochloropsis-derived algae EPA is much sparser than for algae DHA. A 2025 bioavailability RCT (Bailey, PubMed 41096614, a single bioavailability study, not yet independently replicated) reported plasma EPA incorporation from microalgae EPA comparable to fish-oil EPA. No clinical-outcome trials specific to algae-derived EPA are available at scale. Pharmacologically, EPA's activity should not depend on its source, but the empirical evidence base for clinical outcomes from algae EPA remains thin compared to fish-derived EPA. People seeking EPA-specific effects — MDD adjunctive support, inflammation modulation, cardiovascular event-prevention indications — should weigh this evidence gap.

Algae Oil vs Fish Oil — Side-by-Side

Both oils deliver bioequivalent DHA. The choice between them is a multi-dimensional fit decision, not a "which is better" question.

Dimension	Fish oil	Algae oil (Schizochytrium / C. cohnii)	Stronger fit
Cost per mg EPA+DHA	Lower (baseline 1×)	Higher (typically 2–4×)	Fish oil
Clinical evidence depth	Extensive (REDUCE-IT, VITAL, STRENGTH, multiple Cochrane reviews)	Moderate (Arterburn bioequivalence + Bernstein TG meta + DOMInO + Cochrane pregnancy synthesis + Birch infant-formula evidence)	Fish oil for breadth; algae oil for its core domains
EPA content	High (18–30% natural, up to 55% concentrated)	Very low (<3%) for Schizochytrium / C. cohnii; high (25–35%) only for rare Nannochloropsis	Fish oil
DHA content	Moderate (12–22% natural)	High (35–55%)	Algae oil
Marine contaminants (Hg, PCBs, dioxins, microplastics)	Source-chain exposure; refining reduces but does not eliminate; IFOS 5-star and similar certifications reduce risk further	Closed-system fermentation eliminates source exposure; routinely BDL on heavy metals and PCBs	Algae oil
Fishy odor / belching	Common (varies by form and freshness)	Substantially lower (no heme proteins, no TMAO precursors)	Algae oil
Vegan / vegetarian / Hindu / Buddhist suitability	Not suitable (animal source)	Suitable	Algae oil
Kosher / halal certification ease	Possible but supply-chain-dependent	Closed-system fermentation simplifies certification	Algae oil
Pregnancy placental purity	Requires low-contaminant fish source and refining	Zero marine-source contaminants by construction	Algae oil
Infant-formula application	Not used (odor, allergen, contaminant control)	Global regulatory standard (GB 10765, FAO/WHO, FDA 21 CFR 107, EU 2016/127)	Algae oil
Wild-fishery / marine-ecosystem impact	Dependent on wild fishery (~75% of fish oil feeds aquaculture, which extracts more wild fish); MSC certification mitigates	Zero wild-fishery extraction	Algae oil
Allergen profile	Fish / shellfish allergens; cross-reactivity risk for shellfish-allergic consumers	No fish / shellfish allergens; only narrow algae-allergic population excluded	Algae oil
Triglyceride reduction + cardiovascular event prevention	Strong evidence base, including prescription pure EPA (REDUCE-IT) for high-risk secondary prevention	Algae DHA reduces TG (Bernstein meta) but also raises LDL-C; no large CV-outcome RCT	Fish oil (including prescription EPA)
Major depressive disorder adjunctive support	EPA-dominant formulations have RCT support	DHA-dominant Schizochytrium / C. cohnii is not the appropriate match	Fish oil (EPA-dominant)
Brain / vision / pregnancy / infant development	Suitable DHA source	Suitable DHA source (Arterburn 2008 bioequivalence confirmed); zero-contaminant and infant-formula-grade advantages	Tie on efficacy; algae oil's purity and population fit win in this domain

The honest summary, in plain language: algae oil and fish oil are complementary, not competing, omega-3 sources. Algae oil is the right choice for dietary-restriction, religious-observance, placental-purity, infant-formula, and sustainability priorities. Fish oil is the right choice for evidence depth in cardiovascular event prevention, for EPA-specific applications including mood support, and for cost-sensitive supplementation. Many users will benefit most from understanding which one fits which question, rather than from picking a single "winner."

Safety and Regulatory Status

250 mg combined EPA + DHA daily meets the EFSA cardiovascular threshold; 200-300 mg DHA daily for cognitive and visual maintenance per EFSA; pregnancy ≥200 mg DHA per day endorsed by WHO/ISSFAL/EFSA · DOMInO tested 800 mg DHA + 100 mg EPA per day only under obstetric supervision with documented post-term gestation signal.

Safety profile

Algae oil has a strong safety record across decades of use. EFSA's upper safe intake for long-term adult intake of EPA + DHA combined is 5 g per day (EFSA 2012); EFSA's authorization opinion for Schizochytrium sp. oil as a Novel Food specifies that food-supplement EPA + DHA intake of up to 3 g per day for adults (excluding pregnant and lactating women) is safe (EFSA Journal 2020;18(10):6242). The US FDA, in its 2004 letter establishing the qualified health claim for EPA and DHA, advises that combined EPA + DHA from food and supplements should not exceed 3 g per day.

Common observations:

Mild belching / aftertaste: substantially less common than with fish oil, owing to the absence of heme proteins and trimethylamine-N-oxide precursors.
Gastrointestinal discomfort at high doses (nausea, loose stools, bloating): possible, dose-dependent.
Bleeding-time prolongation at intakes above ~3 g per day: theoretical and dose-dependent. Algae oil's DHA-dominance and low EPA content moderate this risk relative to high-EPA fish oils, but users on warfarin, direct oral anticoagulants, clopidogrel, or aspirin should consult their prescriber before supplementing above approximately 2 g per day.
Atrial fibrillation risk at very high (~4 g/d) combined EPA+DHA intake: identified in the STRENGTH trial (PMID 33190147) and discussed by the American Heart Association. Typical algae oil consumption (200–1000 mg DHA per day) is well below this threshold.
Pregnancy / lactation: extensive safety data including DOMInO (n=2,399) and the Cochrane Middleton 2018 synthesis (n=19,927). The DOMInO post-term gestation signal noted above is a real but modest consideration at the 800 mg/d intake level; standard 200–300 mg DHA per day in pregnancy is well-tolerated.
Infants: approximately three decades of infant-formula use globally with no defined long-term safety signal within regulated limits.
Algae allergy: rare but real; people with known algae allergy should avoid algae oil.

Regulatory status across major markets

Market	Authorization channel	Status	Health claims permitted	Key constraints
United States (FDA)	GRAS + DSHEA + infant formula 21 CFR 107 + qualified health claims	Authorized	Qualified Health Claim: "EPA and DHA may reduce the risk of coronary heart disease"; structure/function claims covering brain, vision, pregnancy	Combined EPA + DHA <3 g/d advised for total food + supplement intake
European Union (EFSA)	Reg (EU) 2017/2470 Union List of Novel Foods + Reg 432/2012 health claims	Authorized	Article 13(1): DHA contributes to maintenance of normal brain function (250 mg/d); maintenance of normal vision (250 mg/d); EPA + DHA contributes to maintenance of normal blood triglyceride concentrations (2 g/d). Article 14: maternal DHA intake contributes to normal brain and eye development of the fetus and breastfed infants (+200 mg/d during pregnancy / lactation).	Food-supplement EPA + DHA ≤3 g/d for adults excluding pregnant / lactating; long-term combined intake ≤5 g/d
China (NMPA)	Ministry of Health 2010 Notice No. 3 (Novel Food Ingredient) + GB 10765-2021 (infant formula) + Health Food channel for memory-support claims	Authorized	General food DHA labeling; registered health-food function "auxiliary improvement of memory"	General food: recommended ≤300 mg DHA/d. Infant formula: 0.2–0.5% of total fatty acids (mandatory)
Brazil (ANVISA)	IN 28/2018 Anexo I + RDC 243/2018	Authorized with age restriction	ANVISA Anexo V functional claim: EPA+DHA triglyceride reduction (≥1,500 mg/day) + "source of omega-3". The DHA brain/vision claims are EFSA-authorized only — not ANVISA-authorized.	Food supplements: adults ≥19 years only. Infant formula falls under a separate regulatory channel and may contain DHA. The 2023 VISA/SC suspension of multiple pediatric-positioned algae DHA supplements enforced this restriction; Brazilian consumers should purchase children's DHA only through approved infant-formula or pediatric channels.

How to Choose a Quality Algae Oil

Five criteria, in order of priority:

Third-party verification. Look for IFOS (International Fish Oil Standards, which also certifies algae oil), USP Verified, NSF / Informed Sport, or GOED voluntary-monograph compliance. These programs test for contaminants, oxidation markers (peroxide value, p-anisidine, TOTOX), and label-claim accuracy.
Strain transparency. A reputable algae oil discloses the source microalga — Schizochytrium sp., Crypthecodinium cohnii, Ulkenia amoeboida, or Nannochloropsis sp. This tells you immediately whether the oil is DHA-dominant (the first three) or EPA-dominant (Nannochloropsis), and aligns with the regulatory authorizations covering that strain.
DHA and EPA milligrams stated per serving. Avoid products that disclose only "total omega-3" or "total algae oil" without separating DHA and EPA. The active dose information you need is the milligram amount of each long-chain omega-3.
Closed-system fermentation evidence. Reputable manufacturers describe their production process: closed bioreactor, food-grade carbohydrate substrate, downstream refining (molecular distillation, deodorization), antioxidant protection (mixed natural vitamin E, rosemary extract, ascorbyl palmitate).
Freshness and oxidation. Algae oil, like all polyunsaturated oils, oxidizes. Look for nitrogen-flushed packaging, opaque or dark bottles, and within-spec peroxide value (≤5 meq/kg) and TOTOX (≤26 per the GOED voluntary monograph). Avoid products with a strongly rancid or solvent-like smell.

For vegan, kosher, or halal consumers, also look for the corresponding certification mark (Vegan Society / Certified Vegan, Orthodox Union / Star-K / OK, IFANCA / JAKIM).

References

All algae-specific PMIDs verified against PubMed (2026-05-24). Broad EPA / DHA evidence cross-references live on the Omega-3 cluster hub references section.

Algae-specific clinical and meta-analytic evidence

PMID 18589030 · Arterburn LM, Oken HA, Hall EB, Hamersley J, Kuratko CN, Hoffman JP (2008) · "Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid" · Journal of the American Dietetic Association 108(7):1204–1209 · n=32 RCT, 600 mg DHA/d × 2 wk · bioequivalent plasma + RBC DHA incorporation
PMID 22113870 · Bernstein AM, Ding EL, Willett WC, Rimm EB (2012) · "A meta-analysis shows that docosahexaenoic acid from algae oil reduces serum triglycerides and increases HDL-cholesterol and LDL-cholesterol in persons without coronary heart disease" · Journal of Nutrition 142(1):99–104 · 11-RCT meta · TG ↓ + HDL-C ↑ + LDL-C ↑ (two-direction honesty)
PMID 19145206 · Ryan AS, Keske MA, Hoffman JP, Nelson EB (2009) · "Clinical overview of algae-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors" · Cardiovascular Drugs and Therapy · 16-RCT overview · TG reduction across normo-, hyper-, and statin-treated populations (author affiliations include the algae oil ingredient supplier — disclosure consistent with educational-reference practice)
PMID 25123060 · Maki KC et al. (2014) · "A new microalgae DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia" · Prostaglandins, Leukotrienes and Essential Fatty Acids
PMID 20959577 · Makrides M, Gibson RA, McPhee AJ, Yelland L, Quinlivan J, Ryan P (DOMInO Investigators, 2010) · "Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial" · JAMA 304(15):1675–1683 · n=2,399 · 800 mg DHA + 100 mg EPA/d · primary endpoints negative (maternal depression NS · child cognition NS) · secondary early preterm <34 wk ↓ ~50% (hypothesis-generating) · post-term gestation signal ↑

Regulatory references

FDA GRAS Notice 137 (2004) · Algae oil (Schizochytrium sp.) — FDA "no questions" letter, February 12, 2004. (Multiple subsequent GRAS Notices extend authorization to additional strains.)
EFSA NDA Panel (2020) · Safety of Schizochytrium sp. oil as a novel food pursuant to Regulation (EU) 2015/2283 · EFSA Journal 2020;18(10):6242.
EU Decision 2003/427/EC · Original Novel Food authorization (2003) for Crypthecodinium cohnii-derived DHA-rich oil.
EU Regulation 2017/2470 · Union List of Novel Foods (Schizochytrium sp. oil).
China MOH 2010 Notice No. 3 · Novel Food Ingredient (algae DHA from Schizochytrium sp. / Crypthecodinium cohnii / Ulkenia amoeboida).
China GB 10765-2021 · Infant formula DHA mandatory 0.2–0.5% of total fatty acids.
Brazil ANVISA IN 28/2018 Anexo I + RDC 243/2018 · Food-supplement algae oil restricted to adults ≥19 years (2023 VISA/SC pediatric suspension enforced).

Cross-link evidence cited on the Omega-3 cluster hub (for context)

Cochrane Middleton P et al. (2018), omega-3 in pregnancy: PMID 30480773.
REDUCE-IT (Bhatt et al. 2019), prescription pure EPA in cardiovascular event prevention: PMID 30415628.
STRENGTH (Nicholls et al. 2020), 4 g/d EPA+DHA and atrial fibrillation signal: PMID 33190147.
Birch EE et al. (2005), DHA in infant formula and visual acuity: PMID 15817866.
For the full 18-PMID reference set covering EPA / DHA mechanisms, ALA conversion, cardiovascular outcomes, cognition, vision, mood, and inflammation, see the Omega-3 cluster hub references section.

Cross-link

Parent (cluster hub): Omega-3 Fatty Acids — the upstream reference covering EPA / DHA / ALA across all sources, mechanisms, and clinical evidence.
Sibling — Fish Oil: Fish Oil — the marine-derived omega-3 sibling, with deeper cardiovascular event-prevention evidence and EPA-rich formulations.
Sibling — Krill Oil: Krill Oil — a phospholipid-form marine omega-3 with naturally bound astaxanthin; lower concentration than fish oil but distinct delivery form.
Sibling — Flaxseed (ALA): Flaxseed / ALA — the plant-derived short-chain omega-3 precursor; relevant context for why algae oil is needed by plant-based diets.
Related lifestyle reference: Pregnancy — for the pregnancy-specific DHA discussion in nutritional context.

Educational Disclaimer

Educational content. Not medical advice. Consult your healthcare provider before starting or changing a supplementation regimen, particularly during pregnancy or lactation, if you have a bleeding disorder, are taking anticoagulant or antiplatelet medications, or have a known allergy to algae or related microorganisms.

Frequently Asked Questions

1. What is algae oil, and how is it different from fish oil?

Algae oil is a long-chain omega-3 (mostly DHA) source produced by closed-system fermentation of microalgae — the organisms at the base of the marine food chain that fish indirectly accumulate DHA from. Algae oil is plant-derived and contains no marine contaminants, but it costs more than fish oil and is typically very low in EPA. Fish oil has a broader EPA-and-DHA profile and a deeper clinical evidence base in cardiovascular outcomes, but carries source-chain contaminant and sustainability considerations.

2. How much DHA and EPA does algae oil contain?

Most commercial algae oil (from Schizochytrium sp. or Crypthecodinium cohnii) is 35–55% DHA and less than 3% EPA. Algae oil from Nannochloropsis sp. is the opposite — 25–35% EPA and very little DHA — but is uncommon in retail supplements.

3. Why is EPA so low in most algae oil?

The Thraustochytrid microalgae (Schizochytrium, Ulkenia) and the dinoflagellate Crypthecodinium cohnii synthesize DHA through enzymatic pathways that terminate at C22:6 n-3 (DHA) without significantly producing C20:5 n-3 (EPA). EPA-rich algae oil requires a different microalga — Nannochloropsis — which uses a different pathway.

4. Is algae oil better than fish oil?

Not in a single direction. Algae oil and fish-derived DHA are bioequivalent in head-to-head testing (Arterburn 2008, PMID 18589030). Algae oil is the appropriate choice for vegans, vegetarians, kosher and halal observers, people concerned about marine contaminants during pregnancy, and infant-formula applications. Fish oil is the appropriate choice for cost-sensitive supplementation, for EPA-specific applications (mood support, anti-inflammation), and for cardiovascular event prevention (where prescription pure EPA has the strongest evidence). Many users benefit most from understanding which oil fits which question.

5. Is algae oil safe and appropriate during pregnancy?

WHO, ISSFAL, EFSA, ACOG, and the China dietary guidelines all recommend ≥200 mg DHA per day during pregnancy. Algae oil is a regulator-aligned source with the additional advantage of zero placental exposure to marine contaminants. The DOMInO trial tested a much higher dose (800 mg DHA + 100 mg EPA per day) and found no benefit on its primary endpoints (maternal depression, infant cognition) but did report, as a secondary finding, fewer early preterm births. The same trial also reported a small increase in post-term inductions and caesareans. Discuss higher-dose use with your obstetric care provider.

6. Can babies and children take algae oil?

Infant formula sold globally typically contains algae-derived DHA and is the standard channel for delivering DHA to infants. This is different from buying an algae oil food supplement for a child. In Brazil specifically, ANVISA IN 28/2018 restricts food-supplement algae oil to consumers aged ≥19 years; pediatric-positioned algae DHA supplements were suspended by VISA/SC in 2023. In other markets, parents considering algae oil for children should consult a pediatrician and verify local regulations.

7. Is algae oil suitable for vegans, kosher, halal, or Hindu vegetarian diets?

Yes. Algae oil contains no animal tissue, fish protein, or shellfish allergen and is the only scalable direct source of long-chain omega-3 for plant-based diets. Plant-derived alpha-linolenic acid (ALA, from flaxseed or chia) does not efficiently convert to EPA or DHA in the body — typically below 5% whole-body conversion to DHA in adults — so direct algae oil supplementation is the most reliable route. Look for the relevant certification mark for your dietary tradition.

8. Does algae oil lower triglycerides?

Yes — a 2012 meta-analysis of 11 RCTs (Bernstein et al., PMID 22113870) found that algae-derived DHA significantly reduces serum triglycerides in adults without coronary heart disease. The same meta-analysis also reports that algae DHA modestly raises both HDL-cholesterol and LDL-cholesterol; both directions of the lipid effect should be communicated together. For cardiovascular event prevention in high-risk patients with hypertriglyceridemia, the strongest evidence comes from prescription pure EPA (icosapent ethyl, 4 g/d, REDUCE-IT trial); algae DHA has no comparable large outcome trial.

9. Does algae oil really contain no mercury or PCBs?

Independent contaminant testing on refined algae oil routinely reports heavy metals (mercury, lead, cadmium, arsenic) and PCB sums at below detection limit — below the lower bound of standard laboratory quantification, not merely below regulatory permissible maxima. This is a structural difference: closed-system fermentation does not expose the oil to the marine source chain that biomagnifies these contaminants in fish. No detection method has a true zero floor, so "below detection limit" is the most precise honest statement, not "absolute zero."

10. What are algae oil's most important limitations?

Higher cost than fish oil (typically 2–4×); very low EPA in the dominant Schizochytrium / C. cohnii forms (a poor match for EPA-driven uses such as MDD adjunct or prescription-strength cardiovascular event prevention); the LDL-cholesterol-raising effect alongside triglyceride lowering; the Brazilian ≥19-year age restriction on food-supplement use; and the relatively thin clinical-outcome evidence base specific to algae EPA. These are real and have been integrated into the discussion above; algae oil's case rests on its genuine differentiators, not on hiding its constraints.

← Back to Omega-3 cluster hub · All Ingredients